Impel Pharmaceuticals is the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations. As a result, Impel's therapies have the potential to improve the onset of symptomatic relief for a spectrum of conditions.
Impel's mission is to create and provide transformative therapies for people suffering from diseases with high unmet medical needs. We have pioneered an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
To learn more about Impel Pharmaceuticals, please visit our website at http://impelpharma.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
Jun 15, 2023
Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa Additional Poster Underscores the Need for Non-Oral Treatment Options Given the Prevalence of Pre-Existing Gastrointesti...
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTL...
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
May 10, 2023
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs,...